## An LLM-based Knowledge Synthesis and Scientific Reasoning Framework for Biomedical Discovery

Oskar Wysocki<sup>1,2</sup>, Magdalena Wysocka<sup>2</sup>, Danilo S. Carvalho<sup>2</sup>, Alex Bogatu<sup>2</sup>, Danilo Gusicuma<sup>1</sup>, Maxime Delmas<sup>1</sup>, Harriet Unsworth<sup>2</sup>, André Freitas<sup>1,2,3</sup>

<sup>1</sup>Idiap Research Institute, Switzerland

<sup>2</sup>National Biomarker Centre, CRUK-MI, Univ. of Manchester, United Kingdom <sup>3</sup>Department of Computer Science, Univ. of Manchester, United Kingdom

**Correspondence:** firstname.lastname@idiap.ch<sup>1</sup>firstname.lastname@manchester.ac.uk<sup>2</sup>

Abstract

We present BioLunar, developed using the Lunar framework, as a tool for supporting biological analyses, with a particular emphasis on molecular-level evidence enrichment for biomarker discovery in oncology. The platform integrates Large Language Models (LLMs) to facilitate complex scientific reasoning across distributed evidence spaces, enhancing the capability for harmonizing and reasoning over heterogeneous data sources. Demonstrating its utility in cancer research, BioLunar leverages modular design, reusable data access and data analysis components, and a low-code user interface, enabling researchers of all programming levels to construct LLM-enabled scientific workflows. By facilitating automatic scientific discovery and inference from heterogeneous evidence, BioLunar exemplifies the potential of the integration between LLMs, specialised databases and biomedical tools to support expert-level knowledge synthesis and discovery.

### 1 Introduction

Contemporary biomedical discovery represents a prototypical instance of complex scientific reasoning, which requires the coordination of controlled in-vivo/in-silico interventions, complex multi-step data analysis pipelines and the interpretation of the results under the light of previous evidence (available in different curated databases and in the literature) (Paananen and Fortino, 2019; Nicholson and Greene, 2020). This intricacy emerges out of the inherent complexity of biological mechanisms underlying organism responses, which are defined by a network of multi-scale inter-dependencies (Bogdan et al., 2021). While more granular data is being generated by the evolution of instruments, assays and methods, and the parallel abundance of experimental interventions (Dryden-Palmer et al., 2020), there a practical barrier for integrating and cohering this evidence space into a specific context of

analysis.

Within biomedical discovery, the language interpretation capabilities of Large Language Models (LLMs) can provide an integrative framework for harmonising and reasoning over distributed evidence spaces and tools, systematising and lowering the barriers to access and reason over multiple structured databases, textual bases such as PubMed, enriching the background knowledge through specialised ontologies and serving as interfaces to external analytical tools (e.g. mechanistic/perturbation models, gene enrichment models, etc). In this context, LLMs can serve as a linguistic analytical layer which can reduce the syntactic impedance across diverse functional components: once an adapter to an external component is built it can be integrated and reused in different contexts, creating a monotonic increase of functional components. Complementarily, from a Biomedical-NLP perspective, in order to address real-world problems, LLMs need to be complemented with mechanisms which can deliver contextual control (e.g. via Retrieval Augmented Generation: RAG: access the relevant background knowledge and facts) and perform the analytical tasks which are integral to contemporary biomedical inference ('toolforming').

Emerging LLM-focused coordination frameworks such as LangChain<sup>1</sup>, Flowise<sup>2</sup> and Lunar<sup>3</sup> provide the capabilities to deliver a composition of functional components, some of them under a low-code/no-code use environment, using the abstraction of workflows. While there are generalpurpose coordination frameworks, there is a lack of specialised components for addressing biomedical analyses.

In this paper we demonstrate BioLunar, a suite of components developed over the Lunar environment

<sup>&</sup>lt;sup>1</sup>https://python.langchain.com

<sup>&</sup>lt;sup>2</sup>https://github.com/FlowiseAI/Flowise

<sup>&</sup>lt;sup>3</sup>https://lunarbase.ai

to support biological analyses. We demonstrate the key functionalities of the platform contextualised within a real-use case in the context of molecularlevel evidence enrichment for biomarker discovery in oncology.

### 2 BioLunar

BioLunar enables the creation of LLM-based biomedical scientific workflows using software components with standardised APIs. A workflow is composed of components and subworkflows connected through input-output relationships, and are capable of handling multiple inputs. In the user interface, components are clustered according to their function (see Fig.1). Creating a workflow does not require programming knowledge since components are predefined and merely require data inputs or parameter settings. However, for users who wish to write custom code, 'Python Coder' and 'R Coder' components are provided, enabling the definition of custom methods. These custom components can be saved and subsequently accessed in the 'Custom' group tab.

In the paper we describe an exemplar *biomedical workflow* designed to integrate evidence and infer conclusions from bioinformatics pipeline results. Specifically, the *biomedical workflow* queries expert knowledge bases (KBs) that continuously compile clinical, experimental, and population genetic study outcomes, aligning them with assertions relevant to the significance of the observed gene or variant. It then employs Natural Language Inference (NLI) (via LLM) to integrate and harmonise the evidence space and interpreting the results, culminating in a comprehensive summary for the entire gene set input. This interpretation takes into account the bioanalytical context supplied by the user.

### 2.1 Exemplar Workflow

Next-generation sequencing (NGS) assays play a pivotal role in the precise characterisation of tumours and patients in experimental cancer treatments. NGS findings are essential to guide the design of novel biomarkers and cancer treatments. Nevertheless, the clinical elucidation of NGS findings subsequent to initial bioinformatics analysis often requires time-consuming manual analysis procedures which are vulnerable to errors. The interpretation of molecular signatures that are typically yielded by genome-scale experiments are often supported by pathway-centric approaches through which mechanistic insights can be gained by pointing at a set of biological processes. Moreover, gene and variant enrichment benefits from heterogeneous curated data sources which pose challenges to seamless integration. Furthermore, there are different levels of supporting evidence and therefore prioritising conclusions is crucial. Automating evidence interpretation, knowledge synthesis and leveraging evidence-rich gene set reports are fundamental for addressing the challenges in precision oncology and the discovery of new biomarkers.

### 2.2 User interface

The user interface facilitates an agile workflow construction by enabling users to select and arrange components via drag-and-drop from functionally grouped categories, such as, i.a.: 'Prompt Query' featuring NLI components, 'Knowledge Bases' components, 'Extractors' for retrieving files from zip archives or extracting text and tables from PDF files, and 'Coders', which allow for the creation of custom components using Python or R scripts.

Components allow for individual execution, edition, or configuration adjustment via a visual interface. Workflows can be executed, saved, or shared. Each component has designated input and output capabilities, enabling seamless integration where the output from one can directly feed into another. Users have the flexibility to manually input values if no direct connection is established. Additionally, a component's output can feed into multiple components. The system's architecture supports effortless expansion, adding branches and components without affecting the existing workflow, thus facilitating scalable customization to meet changing requirements. The user interface with an example of a workflow is presented in Fig.1 and in demo video https://youtu.be/Hc6pAA\_5Xu8.

### 2.3 Knowledge bases

The current framework integrates a diverse set of knowledge bases which are relevant for precision oncology. To identify gene mutations as biomarkers for cancer diagnosis, prognosis, and drug response, we integrated CIViC<sup>4</sup> and OncoKB<sup>5</sup>. CIViC provides molecular profiles (MPs) of genes, each linked to clinical evidence, with

<sup>&</sup>lt;sup>4</sup>https://civicdb.org

<sup>&</sup>lt;sup>5</sup>https://www.oncokb.org



Figure 1: BioLunar interface. An exemplary workflow of Gene Enrichment with an input gene set, knowledge base query and LLM interpretation components.

a molecular score indicating evidence quality, assessed by human annotators. The Gene Ontology<sup>6</sup> (GO) offered gene function insights, and the Human Protein Atlas<sup>7</sup> supplied a list of potential drug targets and transcription factors. We employed COSMIC<sup>8</sup> for somatic mutation impacts in cancer, the largest resource in this field. Our analysis also included KEGG<sup>9</sup>, Reactome<sup>10</sup>, and WikiPathways<sup>11</sup> for pathway information, enriching our investigation with scientific literature via PubMed's API <sup>12</sup>.

In the following subsections, we showcase examples of components, subworkflows, and workflows constructed using the BioLunar framework, motivated by the biomarker discovery/precision oncology themes.

# 2.4 Construction and reuse of specialised prompts

BioLunar employs standard LLM interfaces, allowing the use of different models according to users' preferences. The prompt components allows for the composition of specialised prompt chains which can be later reused, defining a pragmatic pathway for specialised Natural Language Inference (NLI) via prompt decomposition/composition. This approach allows for the creation of reasoning chains that combines user's instructions with the results of database queries and analyses from specialised tools within the context of the study. An instantiated example of the *Azure Open AI prompt* is described in Fig.1.

### 2.5 Subworkflow component

The *subworkflow* component enables the reuse of an existing workflow within another workflow, functioning as a component with specified inputs and outputs. This feature simplifies the composition of more complex workflows and avoids the repetition of defining identical steps for the same task. Subworkflows can be selected like other components from the left panel in the interface, offering access to all available workflows for easy integration. Examples of subworkflows are presented in Fig.2,3.

#### 2.6 Gene Enrichment subworkflow

One example of a specialised subworkflow is the *Gene Enrichment subworkflow* (Fig.1,2A) begins with uploading the targeted gene sets. Then a component accesses a specific KB — such as Gene Ontology, KEGG, Reactome, or WikiPathways—defined by the user, using *gprofiler* API<sup>13</sup>. This component identifies gene groups with a statistically significant overlap with the input gene set, according to a Fisher's test, and calculates p-values, recall, and precision. The user then specifies a variable to rank these groups and selects the top N for further analysis. The output includes both a inter-

<sup>&</sup>lt;sup>6</sup>https://geneontology.org

<sup>&</sup>lt;sup>7</sup>https://www.proteinatlas.org

<sup>&</sup>lt;sup>8</sup>https://cancer.sanger.ac.uk/cosmic

<sup>&</sup>lt;sup>9</sup>https://www.kegg.jp/kegg/

<sup>&</sup>lt;sup>10</sup>https://reactome.org

<sup>&</sup>lt;sup>11</sup>https://www.wikipathways.org

<sup>&</sup>lt;sup>12</sup>https://pubmed.ncbi.nlm.nih.gov

<sup>&</sup>lt;sup>13</sup>https://biit.cs.ut.ee/gprofiler/page/apis



Figure 2: A) Gene Enrichment workflow - uses the *gprofiler* API to access i.a. Gene Ontology, KEGG, WikiPathways, Reactome; B) Human Protein Atlas workflow. Compares and interprets the input and reference gene sets.

pretation performed by an NLI component (through LLM) and a table featuring the names, descriptions, and statistics of the top N selected groups.

### 2.7 Human Protein Atlas subworkflow

In the *Human Protein Atlas subworkflow*, given a gene set, an associated external KB is queried by selecting 'Transcription factors' from the HPA database using a dedicated query-database connector. A reusable component, 'Analyze overlap', then identifies genes that overlap and calculates relevant statistics. Similarly to the *Gene Enrichment subworkflow*, the results are interpreted by an promptbased NLI component and presented alongside a table summarising the findings (Fig.2B,A.7).

#### 2.8 CIVIC subworkflow

This *subworkflow* exemplifies a more complex composition of components (Fig.3). This subworkflow initiates by querying the CIVIC database for input genes, yielding, among other things, gene descriptions in clinical contexts, and their variants and molecular profiles (MPs), which are essential for the final interpretation. Additionally, users specify the analysis context, including aspects such as cancer types or subtypes, treatments, populations, etc. Initially, gene descriptions are analysed by a prompt-based NLI component within this defined context. Subsequently, MPs scored below a predefined threshold (set at a MP score of 10) are tagged as *less known*, reflecting lower scientific evidence and ranking by CIVIC annotators. The evidence supporting these lesser-known MPs is then interpreted by a prompt-based NLI component, considering the broader analysis context. Conversely, evidence from *well-known* MPs, scoring above 10, undergoes a similar interpretation process.

For genes without identified MPs in CIVIC, a sequence of components perform further evidence retrieval from PubMed. An NLI module generates context-based keywords for PubMed queries, which are combined with the names of genes lacking MPs. A 'PubMed search' component then retrieves N publications, including metadata, citation counts and MeSH terms (used later for context alignment validation). The abstracts of these publications are interpreted by an NLI module in the context of the analysis.

All clinical evidence interpretations are then succinctly summarised by via a prompt component, taking into account the context of the analysis. These interpretations, along with tabular results, constitute the output.

# **2.9** Bioworkflow - comprehensive analysis for a set of genes.

The exemplar *bioworkflow* composes multiple subworkflows (Fig.4), each dedicated to a specific multi-step and specialised task, which are typically defined by the composition of heterogeneous components, most commonly connectors and query instance components to specialised databases (e.g.



Figure 3: CIVIC evidence analysis workflow. prompt-based NLI components are fed by both the results and context of the analysis in order to produce relevant evidence-based conclusions.

CIVIC, HPA, PubMed, OncoKB), external specialised analytical tools (toolformers for gene enrichment analysis) and chains of specialised interpretation prompts (e.g. selection, filtering, extraction, summarisation). This setup forms a comprehensive workflow which exemplifies the close dialogue between LLMs and genomic analysis, encompassing gene enrichment, comparison with reference gene sets, and access to evidence within an experimental medicine setting. Additionally, it queries PubMed publications within the CIVIC component to seek evidence for molecular profiles not yet described. Its componentised architecture facilitates the extensibility of the workflow with new sources, prompts and external tools. Conclusions drawn from each subworkflow are interpreted within the analysis context, being integrated in a comprehensive summary. All findings are compiled in a report, exported as a PDF file.

### 2.10 Software description

BioLunar uses the *LunarVerse* backend for its operations. LunarVerse is downloaded and installed by the setup script included with the demonstration code. Some of its components need user specific configuration to work, such as private API keys, which are defined in a configuration file indicated in the setup instructions. LunarVerse is distributed under a *open software* license. The workflow can also be operated via a graphical interface (LunarFlow)

Running a workflow can be done in two ways: i) directly, by calling the LunarVerse engine on a specified workflow descriptor file; ii) through the Web interface, by pressing the "Run" button.

The first way is the default one in the demonstration code. It returns a copy of the workflow descriptor, with all component output fields filled, which is then used to extract and filter the desired outputs, based on the component labels. It is also the best way to automate multiple workflow runs and to integrate their outputs into other systems. The supporting code is available at https://github.com/ neuro-symbolic-ai/lunar-bioverse-demo.

### 2.11 Report

The *Bioworkflow*, as outlined in point 2.9, generates a report in PDF (Fig.5) format that begins by outlining the context of the study, analysis details, dates, and software versions at the top. The report is enhanced with hyperlinks for easy navigation to specific sections.

A "General Statistics" table provides a comprehensive overview of key metrics aggregated from all components, aiming to consolidate information for each gene throughout the analysis, with hyperlinks directing to the report sections where this information originates.

Subsequent sections categorise genes into var-



Figure 4: Diagram of the Bioworkflow.

ious tables based on biological aspects and the KBs consulted. These include Molecular Function for genes sharing ontologies, drug target checks based on the Human Protein Atlas, assessments of cancer-related genes, Pathway Analysis and Mapping via WikiPathways, and classification of gene alterations by clinical relevance. By correlating genes with known functional information, the workflow identifies statistically significant enriched terms and summarizes these findings using LLM, which also furnishes evidence.

LLM interprets each table, offering textual conclusions relevant to the analysis context. A final summary, crafted using LLM, synthesizes all results within the given context. Importantly, all LLM interpretations are grounded in concrete evidence, with sources cited alongside the narrative. This approach underscores the rigor of the analysis by highlighting distinct sources that substantiate the relevance of each gene and variant.

### 3 Case study

To demonstrate the capabilities of the *Biowork-flow*, we analyzed outputs in two different scenarios, each producing a distinct set of genes from separate bioinformatics analyses. We entered these gene sets along with their analysis contexts into the *Bioworkflow* and executed it. Subsequently, we qualitatively assessed the output reports (see Fig.A.8,A.9), considering both the statistical data and the interpretations provided by the prompt-based NLI modules.

In Scenario 1, the user aims to explore the unique molecular characteristics of HER2-low breast cancer to determine if it constitutes a distinct category within breast cancer types, where the input genes are ERBB2, ESR1, PIK3CA, CBFB, SF3B. The report shows genomic alterations and genomic signatures that were identified, including ERBB2 amplification, mutations in PIK3CA and ESR1, which are important biomarkers in the selection of breast cancer treatment. For the remaining two genes, evidence was found confirming that these are new, significantly mutated genes for which there is preclinical evidence of actionability in clinical practice.

In Scenario 2, the user aims to discover new genes that could lead to more accurate breast cancer diagnoses, enhancing treatment strategies and addressing the disease's complexity. His numerical analysis resulted in a set of genes (DIXDC1, DUSP6, PDK4, CXCL12, IRF7, ITGA7, NEK2, NR3C1) that require investigation. The report informs that none of the genes is an oncogene (confirmation according to OncoKB), two of the genes



Figure 5: The BioLunar report's overview, produced by Bioworkflow.

are potential drug targets and one is FDA approved drug targets. According to the KEGG-based enrichment analysis, these genes were mainly enriched through several signaling pathways including tumor necrosis factor (TNF) signaling pathway. Using LLMs in conjunction with a PubMed search component, papers were searched in PubMed that describe various gene variants and the genes have been indicated as prospective biomarkers associated with breast cancer.

Note that in scenario 2, for genes lacking molecular profiles in the KB, a search in PubMed was conducted. This approach enables the workflow to automatically uncover and search for non-obvious and previously unknown relationships. Essentially, if a gene is absent from the database, it suggests that its relevance is relatively novel and not yet documented. Therefore, seeking out the most recent publications that describe this gene within the analysis context represents a significant advantage, provided by the workflow that integrates various components.

### 4 Related Work

**Bioinformatics Pipelines** Over the past decade, three scientific workflow management systems such as Galaxy (gal, 2022), Snakemake (Köster and Rahmann, 2012), and Nextflow (Di Tommaso et al., 2017), have been instrumental to bioinformaticians to systematise their complex analytical processes. Nextflow targets bioinformaticians and facilitates gene enrichment analysis, annotate bi-

ological sequences, and perform gene expression analysis by including modules supported by various bioinformatics tools. These workflow systems are currently centred around the composition of specialised bioinformatics software, configuration parameters and supporting datasets, facilitating reuse and reproducibility. In contrast, this paper explores the concept on using LLMs within a specialised workflow environment to support the interpretation and integration of multiple analytical processes.

### 5 Conclusion

In this paper we provided a demonstration of a scientific workflow based on LLMs to support specialised gene analyses using oncology and gene enrichment as a driving motivational scenario. The framework is built using the Lunar framework and allows for the composition of specialised analytical workflows, integrating external databases (Retrieval Augmented Generation), external tools (ToolFormers) and contextualised chains of LLMbased interpretation. The paper highlights that a workflow environment with specialised components for RAG, ToolFormers and a set of specialised prompts-based Natural Language Inference can serve as the foundation for streamlining and automating complex analytical process within a biomedical setting. . We showcase analytical applications within the biomedical domain, particularly in oncology, constructively progressing towards more complex gene analysis workflows. The developed bioworkflow demonstrates the LLMs can be instrumental in enabling a complex endto-end highly-specialised analytical workflow, in a reproducible manner, supporting the integration of heterogeneous evidence, synthesising conclusions and while simultaneously documenting and linking to the data sources within a comprehensive output report. The proposed workflow is based on a low-code paradigm that enables domain experts, regardless of their programming skills, to construct and scientific workflows enabled by generaqtive AI amethods.

### Limitations

- The current demonstration uses external LLMbased APIs but can be adapted to open source LLM models.
- The LLM-based inferences require a critical supporting quantitative evaluation and hallucinations are possible. The current workflow is

motivated by a hypothesis generation process, which is fully human supervised and does not have direct clinical applications.

### Acknowledgements

This work was partially funded by The Ark foundation, by the European Union's Horizon 2020 research and innovation program (grant no. 965397) through the Cancer Core Europe DART project, and by the Manchester Experimental Cancer Medicine Centre and the NIHR Manchester Biomedical Research Centre.

### References

- 2022. The galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2022 update. *Nucleic Acids Research*, 50(W1):W345–W351.
- Paul Bogdan, Gustavo Caetano-Anollés, Anna Jolles, Hyunju Kim, James Morris, Cheryl A Murphy, Catherine Royer, Edward H Snell, Adam Steinbrenner, and Nicholas Strausfeld. 2021. Biological Networks across Scales—The Theoretical and Empirical Foundations for Time-Varying Complex Networks that Connect Structure and Function across Levels of Biological Organization. *Integrative and Comparative Biology*, 61(6):1991–2010.
- Paolo Di Tommaso, Maria Chatzou, Evan W Floden, Pablo Prieto Barja, Emilio Palumbo, and Cedric Notredame. 2017. Nextflow enables reproducible computational workflows. *Nature biotechnology*, 35(4):316–319.
- K.D. Dryden-Palmer, C.S. Parshuram, and W.B. Berta. 2020. Context, complexity and process in the implementation of evidence-based innovation: a realist informed review. *BMC Health Services Research*, 20(81):1472–6963.
- Johannes Köster and Sven Rahmann. 2012. Snakemake—a scalable bioinformatics workflow engine. *Bioinformatics*, 28(19):2520–2522.
- David N. Nicholson and Casey S. Greene. 2020. Constructing knowledge graphs and their biomedical applications. *Computational and Structural Biotechnology Journal*, 18:1414–1428.
- Jussi Paananen and Vittorio Fortino. 2019. An omics perspective on drug target discovery platforms. *Briefings in Bioinformatics*, 21(6):1937–1953.

# A Appendix



Figure A.6: User-defined context of the analysis, including aspects like cancer types or subtypes, treatments, populations, for Scenario 1 and 2.



Figure A.7: Human Protein Atlas workflow in the BioLunar interface.

Context: The an that ch and EF constitue Sample size: 5 Cancer type: breast Biopsysite: primary Center: Informed consent: Sample sent: GENERAL ST. Genes Ge	nalysis focuses on H allenges traditional a RBB2 amplification. I tute a significant port at cancer y site	ER2-low breast can classifications based Despite being opera ion of breast cancer	cer (HLBC), a subtype d on HER2 expression tionally defined, HLBCs s, more				Cancer type:	Bre	e sest Cancer	IIFA @ sostific ;		5. Apr Export report Pipeline version: v2.0. details
and EF constitution Sample size: 5 Cancer type: breast Biopay site: primary Center: Informed consent: Sample sent: GENERAL STJ Genes Ge	RBB2 amplification. I tute a significant port t cancer y site	Despite being opera ion of breast cancer	tionally defined, HLBCs s, more									
Genes Ge	A CARCER y site						Context: Bi w Its	reast cancer rith its incider s heterogene ontributing to	(BC) presents noce steadily risi eous nature con issues like rec	a significant global ng and mortality rat nplicates treatment urrence and drug re	health challenge, es remaining high. strategies, esistance. more	
GENERAL ST	ATISTICS						Sample size: : Cancer type: t Biopsy site: pr Center:	27 breast cancer rimary site				
Genes Ge	Anonos						Sample sent:	Sent.				
In	ene Hallmark 1fo	HPA: drug Va targets Va	ariant Funct Relevance	ional Reported Evidence biomarkers	LLM Desc	ription	GENERAL	L STATISTI	ICS			
ERBB2 Onci e, n	rogen Yes, nore more	FDA El approved L' drug target, more	RBB2 Evide 755S >Oncogeni >Sensitivity CiV >Pub	nce: Investigational, c, OncoKB 1 assertion Response, Cancer repurposing, Med 4 assertions Hypothetical, 2 assertions	ERBB2 (Erb-B2 Receptions) Kinase 2) is a Protein Among its related path Drug-mediated inhibiti signaling and Signaling Mutants. Gene Ontolo annotations related to identical protein bindin	ptor Tyrosine Coding gene. hways are ion of ERB82 g by ERB82 KD ygy (GO) this gene include ng and protein	Genes DUSP6	Gene Info protein coding, more	Hallmark Hi No, more F dr	PA: drug targets Var Potential DU: ug target, EXPRE more	lant Functional Evid SP6 Evid SSION >Sensitivity Ci >Pu	Retevand         Reported processing         LLM Description           mmcc.         Hypothetical, (Response, GC Maded         USP4(Dual Specificity) Prosphates)         Intel processing           Marking Arristica         18.86000 (RAPMAP)         Intel processing         Intel processing         Intel processing           Marking Arristica         18.86000 (RAPMAP)         Intel processing         Intel processing         Intel processing
GO:ME		U	//bat		kinase activity. An imp this gene is EGFR.	portant paralog of						phosphoprotein phosphatase activity. An important paralog of this gene is DUSP7.
Genes	PMID	GO ID	GO term		M Conclusion		GO:MF		PMID	60 ID	60 torm	
ERB82 ESR1 PIK3CA CBF8 SF381 GO:BP				The gene enrichment analysis did not yield any significant results. This means that there were no notable patterns or associations found means that there were no notable patterns or associations found were prevented in notable that the solution of the solution of the part increded in notable that the solution of the go to COMF enrichment statistics		ficant results. This ssociations found ssees or pathways	DIXI DUS PD CXC IRI ITG NEI NR3	DC1 SP6 K4 SL12 F7 SA7 K2 3C1	17689856 20920967	GO:0004883	nuclear glucocorticoid receptor activity	The gree encidence analysis identified a single interaction for nuclear guaccontrol meeting activity, which had a precision of 0.125 and a recal of 11 his suggests that the process of combining with a ordrange in cell activity or function in highly specific to this activity. The provide was 0.0258, more go to GOLM encouncil stitutions
Genes	PMID	GO ID	GO term	u	M Conclusion		GO:BP		DMID.	60 ID	60 tran	
ERB82 ESR1 PIK3CA CBFB SF3B1	21106532	GO:1903037 GO:0006356	regulation of leukocyte cell-cell adhesion regulation of transcription by RNA polymerase I	Gene enrichment analysis findings. Two processes reli polymerase I were identified 0.057 and 0.042. Negative n found to have a precision n leukocyte cell-cell adhesion a go to GO:BP enrichment stat	was performed and re ated to regulation of tra with a precision of 0.4 a egulation of T cell differ of 0.4 and recall of 0.0 and, more listics	esuited in several inscription by RNA ind recall values of rentilation was also 041. Regulation of	DIXI DIXI DIX PDI CXC CXC IXI ITG NEI NEI	DC1 SP6 K4 5L12 F7 K2 K2 SC1	Philo	6010	GO term	Let Oriented According to the give enrichment marginglis table, there were no significant findings. The anappies and on a significant findings are the absolute the significant the significant the dataset analysis of the significant significant significant significant problem of the significant significant significant significant gives to GCLBP enrichment statistics
Genes	PMID	Pathway ID	Pathway Title	u	M Conclusion		Ger	nes	PMID	Pathway ID	Pathway Title	LLM Conclusion
ERBB2 ESR1 PIK3CA CBFB SF3B1		KEGG:05213 KEGG:01522	Endometrial cancer Endocrine resistance	Gene enrichment analysis Endocrine resistance, cent platinum drug resistance wa a high precision (0.75, 0.1 (0.032, 0.029, and 0.028, n these pathways may play a n go to statistics	revealed several sig ral carbon metabolism re all identified as enrici 5, and 0.5, respectivel espectively). These find ole in drug resistance m	gnificant findings. n in cancer, and hed pathways with y) and low recall dings suggest that sore >>	DIX DU PC CXX IR IT NE NR	DC1 ISP6 DK4 CL12 KF7 SA7 EK2 ISC1		102281443 hsa04668	Kaposi sarcoma-associate d herpesvirus infection tumor necrosis factor (TNF) signaling pathway	The gene enrichment analysis did not yield any significant findings. This means that there were no notable enrichment of genes related a particular blocking foreases an indexist. The analysis was a particular blocking foreases and indexist. Inclusion, the means that the second second second second second second means that the second second second second second second second second second second second ge to statistica
REACTOME										hsa04657	IL-17 signaling pathway	
Genes	PMID	Pathway ID	Pathway Title	u	LM Conclusion		Gen	ME	PMID	Pathway ID	Pathway Title	LLM Conclusion
ERBB2 ESR1 PIK3CA CBFB SF3B1	vs	REAC:R-HSA- 8931987 REAC:R-HSA- 8939256	<ul> <li>RUNX1 regulates estrogen receptor mediated transcription</li> <li>RUNX1 regulates transcription of genes involved in WNT signaling</li> </ul>	bit Transcriptional regulation of settogen receiptor mediated signaling WMT signaling by RNXX visa settimetide with a procession of 0.4 recall of 0.333. PDK worths in ERBB2 signaling aboved a precision precision of 0.4 and recall of 0.134. TRAP2 family was four applicable the transcription of growth factors and their receiptors w precision of 0.4 and recall of 0.133. more applicable to transcription of growth factors and their receiptors w precision of 0.4 and recall of 0.133. more			Dixe OUS PDI CXC IRH ITG NEI NR3 WIKIPATH	DC1 5P6 K4 L12 F7 K2 3C1 WAYS				The gene enclotment analysis did not yield any significant findings from the given table. Therefore, no statistically significant enclotment of any gene or pathway was observed. The analysis suggests that the genes and pathways in the sample and not show any significant association with the pendopic table under investigation. This could be a tabletico
Genes	PMID	Pathway ID	Pathway Title	LL	M Conclusion		Gen	nes	Nr of genes	Pathway ID	Pathway Title	LLM Conclusion
ER882 ESR1 PIK3CA CBF8 SF381		WP:WP2814 WP:WP712	Mammary gland development pathway Puberty Stage 2 of 4 Estrogen signaling pathway	Gene enrichment analysis w related to mammary gla inflammation, and breast or pathways intersection size be from 0.4 to 0.6, indicating tha selection. However, the recal go to statistics	eas performed on five bi and development, est ancer. The analysis si only a small number o sing three. The precisi the pathways were syne Il values were generally !	iological pathways trogen signaling, howed that these if genes, with the on values ranged ecific in their gene low, rmore	DIXD DUS PDI CXC IRF ITG NEI NEI CHECK D	DC1 5P6 K4 11,12 F7 K2 3C1 IRUG TARC	GETS BASED	) on HPA		The gene environment analysis do not yield any significant results. The means that no particular gene or set of genes were found to be overropresented or enriched in the dataset under investigation, identified that may be associated with the gene expression patterns in the dataset. This suggests that more get to dataset.
CHECK DRUG	TARGETS BASE	ED ON HPA					Gen	les	FDA approved drug targets	Potential drug targets	Evidence level	LLM Conclusion
Genes ERBB2	FDA approved drug targets	Potential drug targets 0	at protein level	LL One gene (PIK3CA) overlaps reference gene set, Potential a recall of 0.001. The p-value	M Conclusion s between the analysed I drug targets, with a pr is not statistically signif	Igene set and the recision of 0.2 and ficant at 0.267.	DIXC DUS PD	DC1 SP6 K4	0	0 1 0	at protein level	The set of genes being analyzed has two genes, DUSP6 and NEK2, that overlap with the reference gene set Pointeil drug targets. The procession of the overlap is 0.25, meaning a quarter of the analyzed genes are also in the reference set. The recall is very low at 0.002, including that only a small fraction of the reference set is present in the analyzed set. The Fisher's Test result shows a p-value of 0.0797, which is not significant, go to statistice.
PIK3CA	0	1	at protein level	go to statistics		*	CXC CHECK C	ANCER-RE	0 ELATED GEN	0 NES		*
CHECK CANC	ER-RELATED GE	ENES					Gen	ies	Cancer-relate d genes COSMIC Somatio	BC drivers Nik-Zainal 2016		LLM Conclusion
Genes	Cancer-relat d genes COSMIC Somatic Mutations	e BC drivers Nik-Zainal 2016	The given set of gen	LLM Conclus	sion	cision of 1.0 and a	DIX	DC1 SP6	0 0	0	The given set of g number of overlaps 1.0, which is not between the given s	enes (name: 0) has no overlapping genes with the reference set. The is 0, precision is 0.0, and recall is 0.0. The Fisher's Test result (posube) is significant. Therefore, there is no statistical evidence for any similarity et of genes and the reference set. The list of overlapping genes is empty, area there on ourdencino enset. While the overlapping store is empty.
ESR1 PIK3CA	1	1	recall of 0.01, indica but the given set o overlapping genes ar in a p-value of 1.8173 go to statistics	ting that all overlapping genes nly contains a small fraction e SF381, CBFB, PIK3CA, ERE 9584275897554e-08, indicating	were correctly identifie of the genes in the r 382, and ESR1. The Fis a high statistical signifi	ed in the given set, reference set. The sher's Test resulted icance.	CHECK G	K4 SL12 SENE ALTE	0 0 ERATIONS B	0 O Y KNOWN SIGM	precision and recall which means there	values are both 0.0, indicating that there is no overlap. The p-value is 1.0, is no statistical significance. go to statistics
CHECK GEN	E ALTERATIONS	BY KNOWN SIG	GNIFICANCE				Genes	- 1.000 K10	ariant E	Evidence PMI	D Citations	LLM Conclusion
Genes ER8B2	Variant ERBB2 D769Y	Evidence PI >Sensitivity/ 232 Response, CIVIC >Oncogenic , OncoKB	MID Citations 22088 880 0	LL Expression of this mutation and murine B-cell and fibro activating as measured by inci proliferation, colorry formatic mammary cell lines compared go to the evidence	M Conclusion n normal breast epithe blast cell lines demor reased protein and path on in soft agar, and to wildtype, more	alial, breast cancer nstrated that it is way activation, cell transformation of	CXCL1	2 C> DI EXPR	USP6 RESSION KCL12 igulation	PubMed 2216 9 CIVIC PubMed 3846 2	976 143 738 0	Expression of DUSP was associated with sensitivity to MEX which distributions of the sensitivity of the sensitivity of the sensitivity add cancer call lines. The papers highlight the potential of various dispractic and therapeutic targets for breast cancer and related conditions.
FINAL CONCL	USION					*	Ger	nes			F	nal LLM Conclusion
Genes ER882 ESR1 PIK3CA CBFB SF381	Various gen become imp implicated in significantly CCND3. For	omic alterations and ortant biomarkers fo breast cancer (PIK3 mutated genes were CBFB and SF3B1 th	Fina d genomic signatures, i r traatment selection in I (CA, PTEN, AKT1, TP53) i identified including TB3 rere are preclinical evider	I LLM Conclusion ncluding ERB82 amplification, preast cancer (BC). In addition GATA3, CDH1, R81, ML3, M GATA3, CDH1, R81, ML3, M Kore of actionability of use in clin	mutations in PIK3CA, to identifying nearly all WP3K1 and CDKN1B), 3R1, PTPN22, PTPRD, ical practice. go to evide	and ESR1 have genes previously a number of novel NF1, SF3B1 and ence	Dix Dux PD Cxx IR TTC NR	IDC1 SP8 XK4 CL12 IF7 SA7 EK2 3C1	Breast cancer systems biolo interplay in dis from primary FABP4, CXCI druggability. F metastasis. Th advancing our	r metastasis, a leac gy approach to unn sease progression : breast lumors and L12, APOD, and IG urthermore, this re study's significa understanding of b	fing cause of cancer- avel dysregulated gen and offering new aver metastatic sites, critic F1 emerge as potent search reveals the in nee lies in its potenti reast cancer metastas	related motify, entains independently independent in and, entropy, as encores instabilities and issues, and working light on their moterula uses for drug discovers, By integrating transcriptome and interactione dail all genes in the metastatic casader are before. Note that and significant all branepaid is and the significant stabilities of the significant and assimption is a convent of pathways like collapse degradation and assembly in driving is and power by precision metalence approaches, prior indicato a and power by precision metalence approaches, prior indicators

Figure A.8: The BioLunar report, produced by *Biowork-flow* for Scenario 1

Figure A.9: The BioLunar report, produced by *Biowork-flow* for Scenario 2.